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Background: Displaced femoral neck fractures are a significant
source of morbidity and mortality and can be treated with either
hemiarthroplasty (HA) or total hip arthroplasty (THA). Proponents
of THA have argued THA offers lower risk of revision, with
improved functional outcomes when compared to HA. To evaluate
cost effectiveness of THA compared with HA, a trial-based
economic analysis of the HEALTH study was undertaken.
Methods: Health care resource utilization (HRU) and health-related
quality of life (HRQoL) data were collected postoperatively and
costed using publicly available databases. Using EuroQol-5
Dimensions (EQ-5D) scores, we derived quality adjusted life years
(QALYs). A 1.5% discount rate to both costs and QALYs was
applied. Age analyses per age group were conducted. All costs are
reported in 2019 Canadian dollars.
Results: When compared with HA, THA was not cost-effective for
all patients with displaced femoral neck fractures ($150,000/QALY
gained). If decision makers were willing to spend $50,000 or
$100,000 to gain one QALY, the probability of THA being cost-
effective was 12.8% and 32.8%, respectively. In a subgroup of
patients younger than 73 (first quartile), THA was both more
effective and less costly. Otherwise, THA was more expensive and
yielded marginal HRQoL gains.
Conclusions: Our results suggest that for most patients, THA is
not a cost-effective treatment for displaced femoral neck fracture
management versus HA. However, THA may be cost effective for
younger patients. These patients experience more meaningful
improvements in quality of life with less associated cost because
of shorter hospital stay and fewer postoperative complications.
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INTRODUCTION
Hip fractures are the most common injury suffered by
the elderly and contribute substantial morbidity to these
patients, who often have multiple pre-existing comorbidities
and are frail.1 Moreover, the mortality associated with hip
fractures approaches 25% for all patients.2 The burden of
these injuries—in both human and economic terms—is sub-
stantial. Up to 10 percent of patients with these injuries will
require a secondary operation, thus multiplying the economic
impact of these injuries.3 These revision surgeries range from
2 to 3 and half times more costly than the primary procedure.3
For displaced femoral neck fractures, both partial joint
replacement of the hip (hemiarthroplasty, HA) and total joint
replacement [total hip arthroplasty (THA)], are considered
standard of care in the elderly.4 Those who have argued for
HA suggest that it represents a less morbid, less expensive
and noninferior treatment option to THA. Those who argue
for THA believe it yields fewer reoperations, and affords
better quality of life, similar to patients who receive THA
for osteoarthritis.5
A recent meta-analysis suggested that THA for femoral
neck fractures did meaningfully improve quality of life for
patients while reducing unplanned reoperations.4 However,
the meta-analysis was dependent on small, underpowered
clinical trials with non-standardized adjudication of out-
comes. Moreover, issues of confounding due to expertise bias
were pervasive in all studies. Ultimately, even after multiple
studies and meta-analyses,3,4,6 there remains uncertainty
regarding the best treatment for displaced femoral neck frac-
tures in the elderly.
To address this issue, a multi-national, multi-center
expertise-based randomized controlled trial termed the Hip
Fracture Evaluation With Alternatives of Total Hip
Arthroplasty versus Hemi-Arthroplasty (HEALTH) trial7
was performed. The HEALTH study did not find any clini-
cally meaningful differences in either rate of unplanned reop-
erations or health utility when comparing THA to HA. At the
same time that the main trial was undertaken, relevant health
care utilization data was also collected to facilitate an eco-
nomic evaluation to inform health care policy leaders and key
stakeholders in this domain. In this study, we report on the
results of these economic findings through a trial based eco-
nomic analysis.
METHODS
Study Design and Participants
The study design and clinical results of the HEALTH
trial are described elsewhere.7 Health care resource utilization
and health-related quality of life [EuroQol Five-Dimension
(EQ-5D)] information were collected during follow-up visits
at 6, 12, 24, 38, and 52 weeks, and at 18 and 24 months.
Health Care Resource Utilization
A case report form was completed for each follow-up
visit to collect information on health-related quality of life,
secondary procedures, serious adverse events, physiotherapy
visits and hospital readmissions. As the frequency of care was
not captured for physiotherapy, we assumed that patients
would use 7 physiotherapy visits.
The unit costs of secondary procedures were derived
from a patient cost estimator from the Canadian Institute of
Health Information.8 The patient cost estimator is an initiative
which is informed by costing data submitted from all prov-
inces across Canada, with the exception of Quebec. In addi-
tion, costs can be specified by province and by patient age.
For the purpose of this analysis, all cost estimates were taken
from the perspective of the Ontario health care system. Unit
costs of implants were taken from costing inventory at
Hamilton General Hospital in Hamilton, Ontario.
We assumed the hourly rate for provincially covered
physiotherapy was $120.9 Unit costs used in this economic
evaluation are presented in Supplemental Digital Content 1
(see Appendix 1, http://links.lww.com/JOT/B211). All costs
are stated in 2019 Canadian dollars.
Health-Related Quality of Life and QALYs
Although both the Short Form-12 (SF-12) and the EQ-
5D-5L questionnaires were collected in the HEALTH study,
the economic results were derived from the EQ-5D, as this
instrument most easily allows the calculation of a health
utility score, necessary to calculate quality-adjusted life years
(QALYs) and is validated for use in this population.10
QALYs combine quantity of life with health-related quality
of life and are used in cost-utility analyses to compare out-
comes between interventions.
The EQ-5D measures health-related quality of life in 5
dimensions (mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression) with 3 levels of scoring
per attribute. Using a scoring algorithm, the individual
responses to each of the domains are transformed into a
health utility score where 0 represents death and 1 the best
imaginable health state. The minimal important difference for
the EQ-5D was set at 0.05.11 QALYs were calculated for each
intervention by weighting the utility scores by time spent in
health states using an area under the curve approach.
Cost-Effectiveness Analyses
Utilizing a trial-based cost-effectiveness approach fol-
lowing good practice guidelines,12,13 use of THA versus HA
was assessed in incremental cost per QALY gained. Overall
costs and outcomes were first evaluated to determine if either
strategy was dominant (both less costly and better quality of
life). If neither strategy was found to be dominant, incremen-
tal cost-effectiveness ratios (ICERs) were estimated by calcu-
lating the difference in cost between THA and HA divided by
the difference in their effect (ie, QALYs). Uncertainty regard-
ing costs and effects due to sampling variability associated
with the trial was measured using nonparametric bootstrap-
ping techniques.14
The bootstrapping technique entails drawing a random
sample from the original dataset (with replacement) and then
calculating the mean costs and effects associated with each
treatment group (ie, THA and HA). The sampling process
was repeated 2000 times to create a sampling distribution and
generate means, SEs, and 95% confidence intervals (CIs) for
the incremental costs, incremental QALYs, and ICERs. Cost-
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effectiveness acceptability curves (CEACs) were used to
present the probability of THA to be cost effective at different
willingness-to-pay thresholds (ie, $50,000/QALY gained or
$100,000/QALY gained—2 commonly cited cost-
effectiveness thresholds) while taking into account the uncer-
tainty associated with the trial data.15 Analyses were con-
ducted from a public payer and societal perspective over a
2-year time horizon. Both costs and QALYs collected after
one year were discounted at 1.5% per year, as per Canadian
Agency for Drug and Technologies in Health (CADTH)
guidelines, to indicate that either a single QALY or amount
of cost was more valuable now than in one year’s time.16
Sensitivity and Subgroup Analyses
Multiple sensitivity analyses were planned. First, we
planned to assess the impact of change in discount rate,
varying from 0% to 1.5% (base case) to 3%. In addition, we
performed a sensitivity analysis evaluating the difference in
ICERs using a multiple imputation model (base case) and list-
case deletion. Moreover, a sensitivity analysis was planned to
modify the cost of the technology (THA) by 30% in either
direction, as recommended by CADTH.16 Finally, we per-
formed a sensitivity analysis with changing mortality rates
per group if mortality rates were found to be meaningfully
different between THA and HA. We also performed a post-
hoc subgroup analysis by age quartile, hypothesizing that
THA would be most cost effective for younger quartiles.
This analysis mirrors a similar age stratified analysis per-
formed for the main HEALTH trial.
RESULTS
Similar to the results of the clinical trial, there were no
clinically meaningful differences between the 2 treatment
groups in unplanned reoperation or health utility (Table 1).
The costs from the single payer perspective were
estimated to be $32,851 per patient (SE = $2368) for THA
and $27,358 (SE = $2781) for HA. The total number of
QALYs estimated using the EQ-5D score over the two-year
time horizon was 1.40 (SE = 0.02) for THA and 1.36 (SE =
0.019) for HA. The difference of 0.04 QALYs (95% CI:
20.01 to 0.11) was not significantly different. The resulting
ICER of THA compared with HA for the treatment of patients
with displaced femoral neck fractures was calculated at
$151,640/QALY gained (Fig. 1). Table 2 presents these
results.
Our sensitivity analyses produced similar results. When
either a 0% or 3% discount rate was applied to both costs and
QALYs at one year, the ICERs did not meaningfully change.
Finally, when comparing imputed to not imputed EQ-5D
values, EQ-5D scores each decreased by 0.01 points for both
THA and HA, yielding no change in the difference in EQ-5D
scores. In addition, neither decreasing nor increasing the cost
of THA by 30% yielded meaningful differences in ICERs,
because implant costs only represented 10% of total costs per
patient.
Finally, a subgroup analysis by age quartile was
performed. For patients younger than 73 (first quartile),
THA was both less expensive (-$3693) and provided more
health utility (0.10 QALYs). In contrast, for all other age
quartiles, HA provided similar utility at a reduced cost
(Table 3).
The CEACs curves presented in Fig. 2 indicate that
when compared with HA, the probability of THA being
cost-effective for treating operatively managed displaced fem-
oral neck fractures was 12.8% and 32.8%, if decision makers
TABLE 1. Average Cost per Patient (Can $ 2019)
THA HA Difference
P
(N = 718) (N = 723)
Mean (95% CI)Mean (SE) Mean (SE)
Device $1789 $925
Initial procedure cost $16,756 ($1220) $15,732 ($840) $1024 (2$1880 to $3928) 0.10
Physiotherapy $592 ($10.3) $596 ($10.1) $4 (2$23 to $33) 0.74
Costs from adverse events $9469 ($1100) $7933 ($919) $1536 (2$1274 to $4346) 0.28
Costs from second procedures $4231 ($1083) $2541 ($526) $1690 (2$666 to $4047) 0.16
Payer perspective $32,851 ($2368) $27,358 ($1513) $5493 (2$14 to $11,000) 0.06
This represents the average overall costs attributed to each patient by each cost category, though most patients did not suffer from adverse events or undergo second procedures.
FIGURE 1. Cost-effectiveness plane. Editor’s Note: A color
image accompanies the online version of this article.
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were willing to spend $50,000 or $100,000 to gain one
QALY, respectively.
DISCUSSION
To the authors knowledge, this is the most up-to-date
contemporary trial-based economic evaluation comparing THA
versus HA in elderly patients with displaced femoral neck
fractures. Previous studies have concluded, similar to our study,
that THA is likely not a cost effective option in the majority of
patients who suffer femoral neck fractures.17,18 Consistent with
the results of the HEALTH trial and other systematic reviews,
we did not observe any clinically significant differences in either
reoperation or health-related quality of life by treatment group.
Moreover, through a methodologically rigorous trial-based eval-
uation, we were able to assess whether or not THA was a cost-
effective intervention and under what circumstances the treat-
ment may be cost acceptable.
At both $50,000 and $100,000 willingness to pay
thresholds, our cost effectiveness analysis revealed that
compared with HA, THA is not likely to be a cost-effective
intervention for all patients with displaced femoral neck
fractures. Moreover, in no sensitivity analysis did THA
represent a cost-effective intervention. However, in subgroup
analysis, for patients younger than 73 (the youngest quartile),
THA was a cost-effective intervention, because they received
more QALYs for less estimated cost. In contrast, for all other
age quartiles, THA was more expensive and did not provide
more quality of life. Younger patients may be able to mobilize
quicker with a THA as compared to the eldest cohort,
reducing the comparative additional cost to HA. Moreover,
younger patients may notice and appreciate the increased
mobility offered from a THA, leading to higher health-related
quality of life.
Although previous economic evaluations have been
conducted comparing THA to HA, these were either
performed using model approaches with significant assump-
tions or trial-based approaches using small trials.18,19 In a
recent meta-analysis including the HEALTH trial, the
HEALTH trial contributed more than 50% of all patients to
ever be evaluated in a randomized controlled trial comparing
THA to HA.5 The dominance of this trial, in both sample size
and methodologic rigor, necessitates that it be evaluated as a
separate entity and through a single trial-based analysis.
Our study has a number of strengths and some
limitations. As described above, the primary strength is that
our evaluation is based on a multi-national, rigorously-
conducted prospective randomized controlled trial which is
the largest ever in its field. As is true of all trial-based
analyses, using measured outcomes from patients rather than
using modeling practices reduces the number of assumptions
on both costs and utility. In addition, through using a standard
discount rate, performing bootstrapping techniques for sam-
pling uncertainty, and conducting multiple sensitivity analy-
ses determined a priori, we have adhered to good practice
guidelines for trial based economic evaluations.13,16 In addi-
tion, the use of CEACs easily illustrate the likelihood of THA
to be cost-effective at given willingness to pay thresholds.
A notable limitation of our economic evaluation is that
cost and health-related quality of life data were not available
for all patients. Even though EQ-5D scores were absent for
only approximately 8% of observations, relevant cost data
such as medication use and return to work parameters were
not collected throughout the trial. For missing health-related
quality of life data, multiple imputation techniques were used
to generate complete data sets, and subsequent sensitivity
analyses were performed to generate confidence in these
estimates. Regarding return to work, the mean age of patients
enrolled in this trial was 79 years (68 years) and thus patients
would be unlikely to be employed before their injury and to
return to work, regardless of intervention.20 Moreover, cost-
ing data, in particular for orthopedic secondary procedures,
was often not sufficiently specific (eg, all revisions without
infections were costed the same). However, the major cost
driver for these events was length of stay during hospital
readmission and, therefore, the severity of the event was more
TABLE 2. Cost Effectiveness Analysis




Cost THA HA D QALYs
All patients
(N = 1441)
$32,851 ($5275–$194,033) $27,358 ($5211–$144,953) $5493 1.40 (0–1.97) 1.36 (0–1.97) 0.04 (20.01 to 0.09) $151,640
Note that bootstrap sampling data is different than raw trial data and produces marginally different estimates to account for uncertainty.
TABLE 3. Subgroup Analysis of Cost Effectiveness by Age Quartile
Cost Mean QALYs Mean
ICER $/QALY GainedTHA HA D Cost THA HA D QALYs
Age ,73 $24,156 $27,849 -$3693 1.54 1.44 0.10 -$38,175 (dominated)
Age 73–79 $42,441 $26,500 $15,941 1.48 1.45 0.03 $574,220
Age 80–84 $32,709 $21,947 $10,762 1.31 1.32 20.01 -$789,066 (dominated)
Age 85 and older $31,918 $31,978 $-60 1.28 1.22 0.06 -$1072 (dominated)
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accurately captured in costing analysis. Another limitation of
this analysis is the 2-year duration of the HEALTH study. It is
possible that with 2 years of follow-up, all possible costs and
outcomes following surgery may not have been accounted
for. In particular, it may take over 2 years for acetabular
deterioration from a hemiarthroplasty to occur and to require
revision. However, the best available data suggest that health
outcomes following hip fractures take 2 years to stabilize
(including rate of revision operations and functional
outcomes).21
Our analysis provides further evidence as to the cost
effectiveness of THA in the treatment of patients with
displaced femoral neck fractures. We found no meaningful
differences in health-related quality of life between THA and
HA, whereas THA cost over $5000 more per patient.
However, for the youngest cohort of patients, THA was
found to provide meaningful clinical benefit and at less cost.
The cost effectiveness of THA for femoral neck fractures
should be further evaluated prospectively and may justify
reimbursement of the technology for this patient group. The
results of this trial, although most applicable to the single
payer health care system in Ontario, Canada, may be useful in
informing health policy decisions internationally.
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